Clinical-Microbiomics A/S: Financial statements 2025
CVR: 37230634
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Clinical-Microbiomics A/S (CVR 37230634) has filed annual accounts for 2025. In 2025, the company reported a gross profit of EUR 2,831,000 and a net result of EUR -2,586,000 compared with EUR -4,328,000 the year before. That is an increase of 416.6% compared with the year before. Equity in the 2025 report amounted to EUR 85,447,000. The solvency ratio was 92.9%. The company had 115 employees in the financial year.
- Gross Profit
- EUR 2,831,000
- Profit/Loss
- EUR -2,586,000
- Equity
- EUR 85,447,000
- Total Assets
- EUR 91,994,000
- Employees
- 115
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 2.8M EUR | -2.6M EUR | 85.4M EUR | 115 |
| 2024 | - | 548K EUR | -4.3M EUR | 88M EUR | 106 |
| 2023 | - | 1.8M EUR | -2M EUR | 86.3M EUR | 82 |
| 2022 | - | 19M | -6.9M | 119.5M | 32 |
| 2021 | - | 16.8M | -1.7M | 2.8M | 26 |
Official annual report
How creditworthy is Clinical-Microbiomics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Clinical-Microbiomics A/S has published its annual report for 2024. Gross profit came to DKK 548,000, and the net result was DKK -4,328,000.
About Clinical-Microbiomics A/S
Clinical-Microbiomics A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Clinical-Microbiomics ApS. The management consists of Anders Christian Neto de Sousa Grøn. The board consists of Manoj Nirmal Dadlani (chair), Bruce Harvey Grant, Caroline Popper and Isabelle Valerie de Cremoux. The company's owners include MANJIN ApS, VENDLER ApS and Health For Life Capital II Prima S.C.A. RAIF. The company has 32 employees (2026). In 2025, the company reported a gross profit of EUR 2,831,000 and a net result of EUR -2,586,000 compared with EUR -4,328,000 the year before. Equity in the 2025 report amounted to EUR 85,447,000.